

P02-01	Incidence of HPV and HPV related dysplasia in elderly women in Sweden	LINDSTRÖM Annika, Sweden
P06-01	Preliminary results of a phase 2 study of VGX-3100 for the treatment of HPV16 AND/OR HPV18 (HPV16/18) related anal HSIL	BHATT Pankti, United States
P07-01	Efficacy of a coriolus versicolor-based multi-ingredient vaginal gel in HPV+ women older than 40 years: sub-analysis of paloma clinical trial	CORTES Javier, Spain
P08-01	MSWAB™ medium, a non-alcohol-based media for eluting dry self-collected vaginal swabs for hpv detection with commercial assays	CASTRICIANO Santina, Canada
P08-02	Cross-platform high-risk (hr) low occurrence HPV NAAT positive samples for use in nucleic acid detection testing as prospective external quality assessment samples and user defined quality controls	ZHELEV Pavel, Canada
P08-03	Clinical significance of HC2 test borderline results in Slovenian cervical cancer screening program ZORA	VARL Jerneja, Slovenia
P08-04	Five-year cumulative incidence of CIN2+ for women with HPV triage test in Slovenian organized cervical cancer screening program ZORA	KLOBOVES PREVODNIK Veronika, Slovenia
P09-01	Colposcopy, cervical and cone biopsy: the casuistic after implementation of a population screening program	GOMES Inês, Portugal
P09-02	Opportunistic diagnosis of cervical high-grade squamous intraepithelial lesion in a woman with perianal warts	COSTA Fernanda, Portugal
P09-03	Prevalences of STI and HPV in a women's prison in the state capital of São Paulo	ZONTA Marco, Brazil
P10-01	Preference and acceptance of HPV self-sampling: gaining insights on urine as a sample type	FASTER David, Belgium
P12-01	Analytical validation of the Onclarity HPV assay for self-collected specimens	SHAH Millie, United States
P12-02	Post-collection stability of human papillomavirus DNA in first-void urine	VANKERCKHOVEN Vanessa, Belgium
P12-03	Feedback from a colposcopy referral population on the use of Colli-pee for HPV-based cervical cancer screening (CASUS)	BEYERS Koen, Belgium
P12-04	Validation of Floqswabs® for cervical and vaginal physician specimen collection and patient's vaginal self-collected specimens analyzed with the Femofior® screen and HPV quant quantitative real-time PCR assays	KUNASHOVA Anastaciia, Russia
P13-01	Exploring cervical HR-HPV genotypes among asymptomatic women in Grenada, West Indies	BAILEY Ronele, Grenada
P13-02	Human papillomavirus genotype attribution in Wielkopolska region (Poland) – retrospective study	PRUSKI Dominik, Poland
P13-03	HPV16 sublineages related with preinvasive lesions and invasive cervical cancer in Venezuelan women	ALVIREZ FREITES Enrique, Peru
P13-04	Human papillomavirus genotype distribution in a primary screening population in Spain	PEÑATE- GARRIDO Juan Manuel, Spain
P14-01	Current screening tests for cervical cancer detection: review, evidence, and further recommendations	VARGAS Victor Manuel, Mexico

P14-02	Differential expression of microRNAs and their target genes in cervical intraepithelial neoplasias of varying severity	DIMITRIADI Tatiana, Russia
P18-01	Vaginal microbiota and human papillomavirus (HPV) infection among young Swedish women	ÄHRLUND-RICHTER Andreas, Sweden
P22-01	Evaluation of managing CIN 3+-diagnosed pregnant women by methylation assessment using the QIASURE methylation test	HAMPL Monika, Germany
P24-01	Review of predicting factors for an hemorrhagic LLETZ procedure in a representative sample	MICHAIL Georgios, Greece
P25-01	CIN2+ diagnoses between 2013 and 2018 in women 18 to 45 years old – an analysis of German statutory health insurance claims data	HAMPL Monika, Germany
P25-02	The new classification of cervical adenocarcinoma - correlation with histological features and molecular markers	MITRAN Mihai, Romania
P27-01	Serological HPV tumor marker DRH1 shows high sensitivity and specificity for anal dysplasia in people living with HIV	REINHOLZ Markus R., Germany
P28-01	Lack of CD44 overexpression and application of concurrent chemoradiotherapy with cisplatin independently indicate excellent prognosis in patients with HPV-positive oropharyngeal cancer	BIESAGA Beata, Poland
P29-01	Studies of the presence of HPV in adenoid cystic carcinoma of the head and neck region	ZUPANCIC Mark, Sweden
P29-02	Antitumor effects in vitro of FGFR and PI3K inhibitors on HPV positive and HPV negative tonsillar and base of tongue cancer cell lines	KOSTOPOULOU Ourania N., Sweden
P31-01	Real world evidence answering questions about human papillomavirus vaccines effectiveness to prevent genital warts and its relationship with the immunological status in women 14-23 y/o	LÓPEZ-LACORT Mónica, Spain
P31-02	HPV vaccination and decline of HPV 6 and genital warts in population of young women in Germany	DENECKE Agnieszka, Germany
P35-01	Healthcare related costs during 24 months follow-up of patients undergoing cervical conization – a retrospective study of German statutory health insurance claims data	SAXENA Kunal, United States
P35-02	Disease burden of cervical and head and neck cancers in Taiwan: a population-based database analysis	WU Lily, Taiwan
P35-03	Modelling the impact of using a DNA vs mRNA HPV assay as part of the cervical screening programmes in Sweden and Denmark	WESTON Georgie, UK
P35-04	Evaluating the choice of HPV assay for a proposed French cervical screening programme using a health economic model	ADAMS Elisabeth, UK
P35-05	Evaluating the benefits and costs of using an mRNA versus DNA hrHPV assay in the national cervical screening programme in The Netherlands	DOMBROWSKI Caroline, UK
P35-06	Estimating the costs and benefits of HR-HPV assay choice in a theoretical HPV primary cervical screening algorithm in Ontario, Canada	STEBEN Marc, Canada
P36-01	Parental knowledge of HPV and vaccine acceptability in Spain: results from Kappas survey	LÓPEZ Noelia, Spain
P40-01	A prospective cohort study of cervical dysplasia and time-to-pregnancy	KRISTENSEN Mette, Denmark